Immunology and Immunotherapy
DR. JUAN JOSÉ LASARTE AND DR. IGNACIO MELERO
CO-DIRECTORS OF THE IMMUNOLOGY AND IMMUNOTHERAPY PROGRAM
Modulating the immune system is revolutionizing the fight against cancer and infectious diseases. Recent advances show that an individual's immune system can be activated to eliminate tumor cells and extend patients' lives.
We have facilities for producing therapeutic-grade cells and developing and producing gene therapy vectors that allow us to optimize strategies in the clinical development phase and generate new immunotherapy alternatives for patients.
We have long experience developing novel vaccines that have led to patents and the creation of biotechnology companies.
Our innovative work in developing immunomodulation strategies and generating promising immunomodulatory molecules has also been the subject of patents and collaboration contracts with pharmaceutical companies.
We collaborate with pharmaceutical companies to design and develop immunotherapy clinical trials in cancer patients.
Our team comprises nationally and internationally recognized researchers and immunologists from the Clínica Universidad de Navarra. Our oncology research is integrated within the Cancer Center Clínica Universidad de Navarra in several research areas: the Immunotherapy and Advanced Therapies Area, the Melanoma and Non-Melanoma Skin Cancer Research Area, the Liver and Digestive Tumours Research Area and the Urological Tumours Research Area. This union strengthens the interaction between scientists and doctors from the Clínica Universidad de Navarra and researchers from the University of Navarra to develop high-impact translational projects that can lead to examples of personalized medicine.
PROGRAM MANAGERS
| Dr. Ignacio Melero | |
| +34 948 194 700 | |
| imelero@unav.es | |
| Research profile | |
| Dr. Juan José Lasarte | |
| +34 948 194 700 | Ext. 81 3006 | |
| jjlasarte@unav.es | |
| Research profile | |
Oncology research integrated in the
Cancer Center Clinica Universidad de Navarra
Our research groups
We seek to improve therapeutic alternatives against cancer by activating and boosting the immune system
| |
Pablo Sarobe Principal Investigator Curriculum |
| Ignacio Melero Principal Investigator Curriculum |
| Juan José Lasarte Principal Investigator Curriculum |
| |
Pedro Berraondo Principal Investigator Curriculum |
| Sandra Hervás Principal Investigator Curriculum |
| Miguel Fernández de Sanmamed Principal Investigator Curriculum |
| Álvaro Teijeira Sánchez Principal Investigator Curriculum |
| Fernando Aranda Principal Investigator Curriculum |
Objectives of the Research Program in Immunology and Immunotherapy
Development of molecules and immunomodulation strategies
Identify and generate molecules with immunotherapeutic potential and develop immunomodulation strategies.
Therapeutic vaccines
Development of therapeutic vaccines against different types of cancer, infectious diseases and other pathologies.
Adoptive cell therapy
Design and evaluate adoptive cell therapy strategies for the treatment of oncologic diseases.
FROM THE LABORATORY DIRECTLY TO THE CLINIC
Cutting-edge translational research
Our program is transversal and supports other Cima programs to promote, together with the clinical departments of the Clínica Universidad de Navarra, the development of specific reagents for immunomonitoring and the design of immunotherapies for different diseases, which can be applied in clinical activity.
Therapeutic
molecules
We develop vaccines based on dendritic cells increasing their immunotherapeutic effect.
Relationships with companies
Our research has resulted in patents and several collaborations with national and international pharmaceutical companies.
Participation in clinical trials
We collaborate with industry in the development of clinical trials and promote our own clinical trials in collaboration with the Cell Therapy Area of the Clínica Universidad de Navarra.
Would you like to help us?
Thanks to the generosity of many people, the Cima Universidad de Navarra is a reality that strives to offer therapeutic solutions to achieve personalized medicine for patients.